- Home
- FTI vs EXAS Comparison
FTI vs EXAS Comparison
Compare FTI & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FTI | EXAS |
|---|---|---|
| Founded | 1884 | 1995 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.6B | 19.7B |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | FTI | EXAS |
|---|---|---|
| Price | $65.05 | $103.50 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 18 |
| Target Price | $61.42 | ★ $85.64 |
| AVG Volume (30 Days) | ★ 4.0M | 2.1M |
| Earning Date | 05-25-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | 20.42 | ★ 80.32 |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $9,932,600,000.00 | $4,144,000.00 |
| Revenue This Year | $8.54 | $15.18 |
| Revenue Next Year | $5.39 | $12.46 |
| P/E Ratio | $28.25 | ★ N/A |
| Revenue Growth | ★ 9.35 | N/A |
| 52 Week Low | $22.12 | $38.88 |
| 52 Week High | $68.29 | $103.87 |
Technical Indicators
Market Signals| Indicator | FTI | EXAS |
|---|---|---|
| Relative Strength Index (RSI) | 68.05 | 67.47 |
| Support Level | $58.67 | $102.12 |
| Resistance Level | N/A | $103.77 |
| Average True Range (ATR) | 2.20 | 0.27 |
| MACD | -0.20 | -0.10 |
| Stochastic Oscillator | 70.37 | 77.78 |
Price Performance
Historical ComparisonAbout FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.